Tenaya Therapeutics and Alnylam Pharmaceuticals announced a research collaboration on March 5, 2026, to identify and validate up to 15 genetic targets for cardiovascular disease treatments 1 4 Tenaya will receive up to $10 million in upfront payments plus research funding reimbursement over a two-year validation term 1 4 Tenaya is eligible to receive up to $1.13 billion in development and commercial milestone payments if all validated targets lead to approved therapeutics 1 4 Alnylam will assume responsibility for all development and commercialization activities of any resulting therapeutics 1 4 The partnership combines Tenaya's expertise in genetic target identification and validation with Alnylam's leadership in RNA interference (RNAi) therapeutics 1 3 Tenaya's existing pipeline includes gene therapies for hypertrophic and arrhythmogenic cardiomyopathies and a small molecule HDAC6 inhibitor 3 Tenaya shares rose approximately 10-12% in premarket trading followi...
- Get link
- X
- Other Apps